Keenova Therapeutics (formerly Mallinckrodt Pharmaceuticals)

In July 2025, Mallinckrodt merged with Endo, and the combined entity rebranded to Keenova Therapeutics and spun off Par Health as a separate entity. Prior to the merger and rebranding, Mallinckrodt had a history of divisive corporate policies and practices. It is unclear whether these causes or policies were retained, modified, or discontinued by Keenova Therapeutics (1)(2). Keenova promotes divisive sex and gender policies. Its Supplier Code of Conduct requires international vendors to include sexual orientation in their nondiscrimination policy (3). However, Keenova has not publicly canceled customers, suppliers, or vendors based on political views or religious beliefs (4). Mallinckrodt received a score of 100 on the 2025 Corporate Equality Index (CEI) from the Human Rights Campaign (HRC), a political stakeholder group. The company recruits employees based on sexual identity issues. The company discriminates against vendors that do not promote divisive sex and gender policies, indicating it prioritizes sexual issues over merit (5)(6).

Keenova does not appear to discriminate against charitable organizations based on views or beliefs (1). Mallinckrodt’s HRC 2025 CEI rating indicates the company will not donate to non-religious charities unless they embrace controversial sexual identity policies (2)(3). Mallinckrodt’s charitable giving guidelines required that organizations abide by its nondiscrimination policy, including on the basis of sexual orientation and gender identity, thereby excluding some religious charities (4).

Keenova protects its employees against viewpoint discrimination (1). Mallinckrodt’s HRC 2025 CEI rating indicates the company forces employees to attend multiple, controversial trainings on gender identity, sexual orientation, transgender issues, and divisive racial ideology. The company provides gender transition guidelines for its employees and a specific benefits guide with a comprehensive explanation of transgender services funded by the company (2)(3).

Keenova has not supported ideological causes or policies (1). Mallinckrodt’s HRC 2025 CEI rating indicates the company agrees to allow a controversial stakeholder group focused on sexual identity issues to dictate marketing or advertising strategy. By doing so, the company risks dividing employees, alienating customers and harming shareholders (2)(3). Mallinckrodt signed an open letter endorsing the Equality Act, a contentious proposal to amend the 1964 Civil Rights Act by adding sexual orientation and so-called gender identity as protected categories. The legislation would, among other implications, grant biological men access to women-only spaces such as sports teams and public restrooms, and compel healthcare providers to deliver sex-denying healthcare (4). Mallinckrodt’s CEO Mark Trudeau signed the Business Roundtable’s 2019 Statement on the Purpose of a Corporation, which promotes stakeholder capitalism over traditional obligations to shareholders (5). Mallinckrodt supported ESG within its business practices. From its website: “We believe Environmental, Social and Governance (ESG) is foundational to creating long-term value for all of our stakeholders. Mallinckrodt is committed to making ESG a strategic imperative for the company, building a robust program and reporting our progress transparently” (6).

Keenova has not used corporate funds to advance ideological causes, organizations, or policies (1). Mallinckrodt’s HRC 2025 CEI rating indicates the company covers transgender related costs for its employees and their children, including paid short-term leave, puberty blockers, cross-sex hormones, chest surgeries, genital surgeries, medical visits and lab monitoring, travel and lodging. Additionally, the company has pledged philanthropic support of at least one organization or event that promotes sex and gender ideology. By allowing a political stakeholder group to dictate operations, the company increases health care costs and risks dividing employees, alienating customers and harming shareholders (2)(3). Mallinckrodt was a corporate partner of the National LGBT Chamber of Commerce (4). Mallinckrodt was a gold sponsor of Jersey Pride and was an active sponsor of national and local organizations that advocate for LGBTQ equality (5).

“Keenova’s political and lobbying activities (including contributions made by the Keenova Political Action Committee) take place without regard to the personal preferences or affiliations of team members”, and its “public policy initiatives are subject to robust oversight…and exclusively consider the company’s interests” (1). In 2026, Keenova donated to the Equality PAC (2). Since its merger and rebranding, Keenova has not engaged in lobbying (3)(4). Mallinckrodt’s HRC 2025 CEI rating indicates the company publicly advocated for controversial sex and gender ideology through local, state or federal legislation or initiatives. By allowing a political stakeholder group to dictate operations, the company risks dividing employees, alienating customers and harming shareholders (5)(6). Mallinckrodt donated to the Equality PAC and the LGBTQ Victory Fund, which is a national organization dedicated to electing LGBTQ+ people who can further LGBTQ issues at all levels of government (7)(8)(9). Mallinckrodt did not use its lobbying for ideological purposes (10).